Trial reportPsychiatry research2012
Baseline mood-state measures as predictors of antidepressant response to scopolamine.
Trial report in Psychiatry research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04211961 (A Randomised Double-Blinded Placebo-Controlled Trial to Assess the Efficacy and Safety of Scopolamine Compared to Placebo in Individuals With Bipolar Disorder Who Are Experiencing a Depressive Episode), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomised Double-Blinded Placebo-Controlled Trial to Assess the Efficacy and Safety of Scopolamine Compared to Placebo in Individuals With Bipolar Disorder Who Are Experiencing a Depressive Episode
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The placebo effect and its clinical associations in gambling disorder.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists · 2017Pooled it
- Clinical predictors of ketamine response in treatment-resistant major depression.The Journal of clinical psychiatry · 2014Trial
- Potential of pretreatment neural activity in the visual cortex during emotional processing to predict treatment response to scopolamine in major depressive disorder.JAMA psychiatry · 2013Trial
- Duration of untreated illness in gambling disorder.CNS spectrums · 2024Article
- Article
- Interaction effect of serum serotonin level and age on the 12-week pharmacotherapeutic response in patients with depressive disorders.Scientific reports · 2021Article
- Transient Stimulation with Psychoplastogens Is Sufficient to Initiate Neuronal Growth.ACS pharmacology & translational science · 2021Article
- Cholinergic regulation of mood: from basic and clinical studies to emerging therapeutics.Molecular psychiatry · 2019Review
- Article
- Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine.Current neuropharmacology · 2017Review
- Amygdala response to explicit sad face stimuli at baseline predicts antidepressant treatment response to scopolamine in major depressive disorder.Psychiatry research. Neuroimaging · 2016Article
- Cortical abnormalities and association with symptom dimensions across the depressive spectrum.Journal of affective disorders · 2016Article
- Ventral tegmental area cholinergic mechanisms mediate behavioral responses in the forced swim test.Behavioural brain research · 2015Article
- Pretreatment Differences in BOLD Response to Emotional Faces Correlate with Antidepressant Response to Scopolamine.The international journal of neuropsychopharmacology · 2015Article
- Article
- Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses.Biological psychiatry · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Identifying predictors of antidepressant response will facilitate the successful treatment of patients suffering from depression. Scopolamine produces robust antidepressant responses in unipolar and bipolar depression. Here we evaluate the potential for baseline self-ratings to predict treatment response to scopolamine. Fifty-one unipolar and bipolar patients participated in a double-blind, placebo-controlled crossover trial. Following a single-blind placebo session, participants randomly received P/S or S/P (P=3 placebo; S=3 scopolamine (4μg/kg) sessions). Mood-state self-ratings (Profile of Mood State (POMS) and Visual Analog Scales (VAS)) and depression severity (Montgomery-Åsberg Depression Rating Scale (MADRS)) were obtained before each infusion. Day 1 (baseline/placebo) self-ratings were used in a discriminant function analysis to identify linear combinations of individual items that predict response. The discriminant analysis significantly separated responders from non-responders in both the unipolar and bipolar diagnostic subgroups. The discriminant functions accurately classified over 85% of patients as responders/non-responders. The POMS depression subscale significantly correlated with clinical response, as did the VAS restlessness, sad, and irritated scales. These results indicate that self-report mood-ratings obtained before treatment can predict response outcome to scopolamine, and suggest that a constellation of mood-state features may be related to clinical response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.